US Patent
US9289382 — Vaginal inserted estradiol pharmaceutical compositions and methods
Formulation · Assigned to TherapeuticsMD Inc · Expires 2032-11-21 · 7y remaining
Vulnerability score
25/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects pharmaceutical compositions of solubilized estradiol encapsulated in soft capsules for vaginal insertion to treat vulvovaginal atrophy.
USPTO Abstract
According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.
Drugs covered by this patent
- Estrace (ESTRADIOL) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.